Titan Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Titan Pharmaceuticals has a total shareholder equity of $4.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.4M and $356.0K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.09m |
| Equity | US$3.99m |
| Total liabilities | US$356.00k |
| Total assets | US$4.35m |
Recent financial health updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10
Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Financial Position Analysis
Short Term Liabilities: TTNP's short term assets ($4.4M) exceed its short term liabilities ($356.0K).
Long Term Liabilities: TTNP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TTNP is debt free.
Reducing Debt: TTNP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TTNP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TTNP has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.